Recent advances in the use of opioids for cancer pain by Droney, Joanne & Riley, Julia
© 2009 Droney and Riley, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Pain Research 2009:2 135–155
Journal of Pain Research
135
R e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Recent advances in the use of opioids  
for cancer pain
Joanne Droney 
Julia Riley
Palliative Medicine Department, Royal 
Marsden Hospital, London, UK
Correspondence: Joanne Droney 
Palliative Medicine Department, Royal 
Marsden Hospital, London, UK  
Tel +44 20780 82761 
email jodroney@hotmail.com
Abstract: Opioids are the mainstay of treatment for moderate to severe cancer pain. In recent 
years there have been many advances in the use of opioids for cancer pain. Availability and 
consumption of opioids have increased and opioids other than morphine (including methadone, 
fentanyl, oxycodone) have become more widely used. Inter-individual variation in response 
to opioids has been identified as a significant challenge in the management of cancer pain. 
Many studies have been published demonstrating the benefits of opioid switching as a clinical 
maneuver to improve tolerability. Constipation has been recognized as a significant burden in 
cancer patients on opioids. Peripherally restricted opioid antagonists have been developed for the 
prevention and management of opioid induced constipation. The phenomenon of breakthrough 
pain has been characterized and novel modes of opioid administration (transmucosal, intranasal, 
sublingual) have been explored to facilitate improved management of breakthrough cancer pain. 
Advances have also been made in the realm of molecular biology. Pharmacogenetic studies have 
explored associations between clinical response to opioids and genetic variation at a DNA level. 
To date these studies have been small but future research may facilitate prospective prediction 
of response to individual drugs.
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Introduction
Most patients with cancer experience pain at some stage in their illness and many of 
these require opioid analgesia. For the past 20 years cancer pain has been managed 
according to the World Health Organization (WHO) analgesic ladder. This three-step 
ladder recommends sequential increases in the strength of analgesia, starting with 
paracetamol (step 1), adding in a weak opioid (step 2) if the pain persists and finally 
progressing to a strong opioid (step 3) if pain is still not controlled.1 The use of the 
analgesic ladder has been validated in numerous studies and can result in over 80% 
analgesic control.2,3
There have been a number of developments in the use of opioids for cancer pain 
in recent years including:
•  Choice and availability of opioids
• The use of alternative opioids to morphine and opioid switching
• Advances in the methods of delivery of opioids for cancer pain
•   Advances in the methods of managing opioid-induced side-effects, particularly with 
the advent of opioid antagonists
•   An increased knowledge and awareness of the molecular basis for opioid effect 
including pharmacogeneticsJournal of Pain Research 2009:2 136
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Much of the research on opioids has initially been carried 
out in a non-malignant setting, often involving experimental 
pain studies. Some of these data however can be extrapo-
lated to a certain degree to cancer patients. Most of these 
studies influence the direction of research in the use of 
opioids for cancer pain. All of these advances have improved 
individualized pain management and pave the way for the 
future of pain medicine ie personalized prescribing.
Recent advances in the use 
of opioids for cancer pain: opioid 
availability and choice
Morphine is the WHO first line strong opioid of choice 
for cancer pain.1,4 This recommendation is based on 
availability and cost rather then evidence of superior efficacy 
or tolerability. Despite this recommendation, however, 
until relatively recently morphine was unavailable or not 
commonly used in many countries. In 1991 twenty coun-
tries accounted for 86% of morphine consumption.5 In 2006 
Europe and North America accounted for 89% of global 
morphine consumption with developing countries, which 
account for 80% of the world’s population only consuming 
6% of worldwide morphine.6 Reasons for this inequality in 
morphine use/availability include:
•    Inadequate health care infrastructures or pain control as a 
low priority item in a country’s national health agenda
•    Lack of knowledge/skills in pain treatment. Even in the 
US, in a survey of 897 physicians, reluctance to prescribe 
opioids for cancer pain was cited by 61% of respon-
dents.7
•    Legal and regulatory issues surrounding the use and avail-
ability of opioids.8
•    Fear of addiction and misuse or re-direction of opioids into 
the illegal drug trade.9
In 1984 the WHO Cancer Pain Relief Programme was 
established in which a country’s morphine consumption was 
considered to be an indicator of progress to improve cancer 
pain relief.1,5 Between 1984 and 1992, global consump-
tion of morphine increased by nearly 300%.5,10 Since then 
morphine availability has increased worldwide and it has 
been introduced to many more countries. Other alternative 
opioids have also become more widely available, although as 
with morphine, availability and consumption is not uniform 
worldwide, eg, 94% of oxycodone is consumed by USA, 
UK, Canada, Germany, and Australia.6
There have been very few large randomized controlled 
trials comparing different opioids thus there is little 
evidence suggesting superiority of one opioid over another.4 
Some opioids differ in their mode of metabolism and 
therefore some are recommended as being safer in some 
circumstances than others, eg, alfentanil in renal failure. 
Table 1 details some of the common opioids used in the 
management of cancer pain. In a recent survey of 3030 
cancer patients across Europe, morphine (oral or systemic) 
was the most commonly used strong opioid (50%), followed 
by fentanyl (14%), oxycodone (4%), methadone (2%) and 
hydromorphine (1%).11 There are marked differences in the 
choice of 1st line strong opioid in different countries, eg, 
in Belgium it is fentanyl while in Finland it is oxycodone.11 
The differences in choice of opioid and opioid consumption 
was also shown in a study comparing opioid consumption 
in Denmark, Finland, Germany, Iceland, The Netherlands, 
Norway, and Sweden.12
Recent advances in the use 
of opioids for cancer pain: opioid 
switching
As more opioids have become available for use and as famil-
iarity and knowledge about these different opioids increases, 
opioid switching has become a therapeutic maneuver which 
has become widespread in recent years.
Most patients who are prescribed morphine for cancer 
pain achieve good pain control without problematic side-
effects. These patients are known as “morphine responders”. 
A significant proportion of patients however (up to 30%) 
do not respond well to morphine.13 These “morphine non-
responders” present in a number of different ways:14
•    Patients who achieve good analgesia but with intolerable 
side-effects
•    Patients who do not achieve good analgesia because of 
dose-limiting side-effects
•    Patients who do not achieve good analgesia but do not 
experience side-effects either, despite escalating morphine 
doses
Morphine “non-responders” often benefit from chang-
ing to an alternative opioid in a practice known as “opioid 
switching”. The same principle applies for patients who do 
not respond well to any other opioid also. When used care-
fully the practice of opioid switching is a powerful therapeutic 
tool in the individualization of cancer pain management.
The terms “opioid switching” and “opioid rotation” are 
often used interchangeably in the literature. For the purpose 
of this review opioid switching refers to the use of an alter-
native opioid for the purpose of improving analgesia and Journal of Pain Research 2009:2 137
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reducing intolerable side-effects. Opioid rotation is taken 
to refer to the use of an alternative opioid because of avail-
ability, patient or physician choice or a change in the route 
of administration of the opioid. In some studies patients 
undergoing opioid switching and opioid rotation are included 
together.15,16
A Cochrane review in 2004 examined the evidence base 
for the effectiveness of opioid switching to improve drug 
tolerability. Fifty-two studies were included in this review, 
including 23 case reports, 15 retrospective studies or audits, 
and 14 prospective uncontrolled studies. All studies except 
one reported opioid switching as a beneficial clinical practice. 
The numbers of patients included in these studies tended to 
be small. At that time no randomized controlled trials or 
prospective controlled studies had been carried out in this 
area. Therefore the conclusion of the systematic review was 
that there was no substantial evidence to support the practice 
of opioid switching. The author called for further research in 
a number of areas: 1) to establish the true efficacy of opioid 
switching and 2) to determine which opioid should be used 
first line and second line.17
A further systematic review in 2006 suggested that opi-
oid switching is associated with improvement in response 
to opioids in at least 50% of patients.14 A more detailed 
look at some of the larger studies suggests that careful opi-
oid switching may in fact be associated with much higher 
response rates. Table 2 details the results of some of the 
largest studies in this area.
The only prospective case-controlled study of opioid 
switching was carried out using morphine as the first line 
strong opioid of choice for cancer pain with oxycodone 
as second line. The study, which included 186 patients, 
comprised 2 cohorts. 74% (138/186) were morphine 
“responders”, who had been on morphine for at least 4 weeks 
and who had good pain control with minimal side-effects. 
26% (48/186) were morphine “non-responders” who had 
either poor pain control and/or intolerable side-effects despite 
adequate morphine dose-titration. Switching from morphine 
to oxycodone in the morphine non-responder group resulted 
in an overall 96% (179/186) good clinical outcome in terms 
of pain and side-effect profile.18
Two studies have examined the reasons why some 
patients do not have a successful outcome after opioid switch-
ing. In the study by Mercadante et al no association was found 
with clinical factors (including age of patient, gender), type 
or dose of opioid, pain type, the use of adjuvant medications 
or renal impairment. Patients in this study who had both poor 
pain control and adverse opioid effects were more likely 
to be unsuccessful in switching (P = 0.004). However the 
numbers of patients who did not respond to opioid switching 
in this study was small (N = 15/118) therefore it is difficult 
to extrapolate these data into meaningful clinical practice. 
Eight patients in this study required intrathecal pain manage-
ment.16 In the study by Riley et al 5/48 patients did not have 
a successful outcome after opioid switching. One of these 
required an epidural and the authors suggest that for 3 others 
anesthetic intervention would have been appropriate.18
If a switch from one opioid to another is unsuccessful a 
number of factors should be taken into consideration:
•   A further opioid switch may be indicated. More than 
1 opioid switch is sometimes required to achieve an opti-
mum balance between analgesia and side-effects.16,18,19
• The pain may not be opioid responsive
•    Central delivery of opioids may be required (via the epi-
dural or intrathecal route)
•    Other factors may be contributing to the side-effects expe-
rienced, eg, renal impairment, concurrent medications, 
factors related to the underlying disease.
After on opioid switch is undertaken it usually takes a 
few days to achieve a good outcome. Time to stabilization 
on the second opioid may be slightly longer if the patient was 
switched because of both pain and side-effects.16
The dose of the original opioid at which an opioid switch 
is required varies widely. In 1 study in which 54 patients 
were switched from morphine to methadone, the median 
daily morphine dose was 200 mg (range 30 to 1000 mg).20 
In another study the morphine equivalent daily dose was 
577 ± 1535 mg.19 In the prospective controlled study in which 
morphine non-responders were switched to oxycodone, the 
median dose of morphine at time of switching was 70 mg 
(range 15 to 580 mg).18
Similarly the duration of the initial opioid therapy is vari-
able. In one study patients were on the initial opioid for a 
median of 44 days (range 20 to 240 days).20 In another study 
the mean duration of the previous opioid therapy is reported 
as 25.8 weeks (180.6 days) (range 1 to 104 weeks).21 These 
data may suggest that there are 2 broad groups of patients 
which undergo opioid switching. The first group require 
switching shortly after initiation of the initial opioid, when 
the opioid dose is relatively low. The second group appear to 
become non-responsive to the initial opioid at either higher 
doses or after some time has elapsed, perhaps due to changes 
in the underlying painful state, disease, tolerance or some 
other contributing factor.
One of the most challenging aspects of switching from 
one opioid to another is deciding on the starting dose of Journal of Pain Research 2009:2 138
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the second opioid. Although equianalgesic dose ratios are 
available, these are merely guidelines to the relative potencies 
of different opioids. These ratios were derived largely from 
single dose studies and do not take into account individual 
patient factors which may contribute to effect, such as previ-
ous opioid therapy, opioid tolerance or underlying disease.22,23 
The reported equianalgesic dose ratios between opioids also 
may be quite variable depending on the study. The generally 
accepted equianalgesic dose ratio for oral morphine: oxyco-
done lies between 1:1 and 1:2.22 In 1 study the median dose 
ratio of morphine: oxycodone was 1.7 with a broad range 
from 0.25 to 12.24 To make matters even more complicated 
the equianalgesic dose ratios may change according to the 
initial opioid dose, as has been proposed when switching mor-
phine to methadone.20 One of the major factors contributing 
to the difficulties in determining the dose of the alternative 
opioid is the phenomenon of opioid tolerance. This is defined 
as a reduction in response to a drug after repeated admin-
istration. Tolerance to both opioid induced analgesia and 
side-effects may occur, although not necessarily in tandem 
together.25 Incomplete cross tolerance to different opioids 
exists, which may be explained in part by differing pharma-
codynamic and pharmacokinetic factors. There appears to be 
no defined relationship between the dose of the initial opioid 
dose at time of switching and the final stable opioid dose 
after switching.14,16 In some cases opioid switching facilitates 
upward dose titration to achieve good analgesia.26 In others 
the final equivalent dose of opioid required was reduced.19 
These data demonstrate the importance of individualized dose 
titration when switching opioids.14 Most authors recommend 
deciding on the dose when opioid switching in the context 
of a) the individual patient experience (ie, whether switch-
ing because of uncontrolled pain or side-effects) and b) the 
type of opioid used. Conservative dose ratios22 and an initial 
dose reduction of the equianalgesic dose by 25% to 50%22,23 
are recommended with subsequent careful individualized 
dose titration.
Recent advances in the use 
of opioids for cancer pain: 
pharmacogenetics
To date no clinical factor has been identified which can fully 
explain inter-individual variation in response to opioids. 
One of the most recent advances in the use of opioids for 
cancer pain is the interest in pharmacogenetics: how an 
individual’s genetic makeup may influence variability in 
opioid response. The hypothesis held by many researchers is 
that changes at a molecular level in opioid’s pharmacokinetic Journal of Pain Research 2009:2 140
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and pharmacodynamic pathways may be responsible for 
altered opioid response.27 These changes may be brought 
about by genetic variation at a DNA, RNA, or protein level. 
Pharmacogenetics is used in a number of areas of medicine 
including oncology and hematology to prospectively predict 
an individual’s response to certain drugs including warfarin 
and irinotecan.28–30 In cancer pain management pharmacogen-
tics may potentially allow prospective prediction of response 
to different opioids and facilitate choosing the correct dose 
of the correct drug for the correct patient, ie, personalized 
prescribing.
DNA variation: single nucleotide 
polymorphisms
DNA is made up of two opposing strands of nucleotides, 
with each nucleotide consisting of 1 of 4 bases (adenine 
[A], guanine [G], thymine [T], and cytosine [C]), a sugar 
and a phosphate bond. The most common type of genetic 
variation at the DNA level consists of a single change in a 
nucleotide at a particular position along the DNA strand: 
a single nucleotide polymorphism (SNP). SNPs may occur 
at any point in a gene and may be associated with a change 
in the amino acid sequence produced because a) they 
are located in a coding area of the gene b) through influence 
on transcription activity or c) because they are in linkage 
disequilibrium (in a non-random association) with another 
significant polymorphism.
One of the best characterized pharmacogenetic phe-
nomena involves codeine. Codeine is metabolized to 
morphine via the genetically heterogenous enzyme CYP2D6 
(debrisoquine/spartenine hydroxylase).31 Up to 10% of Cau-
casians (and varying proportions of other populations) lack 
CYP2D6 activity. These are known as “poor metabolizers” 
and thus experience little analgesia from codeine, as com-
pared to “extensive metabolizers.32 CYP2D6 gene duplication 
on the other hand is associated with ultra-rapid metabolism 
Table 2 Efficacy of opioid switching
Author Type of study Number of  
patients 
undergoing 
opioid switch
Successful 
outcome  
after opioid 
switching
Reason for switching Comment
Mercadantea,16 Prospective 
uncontrolled study
118 87% Uncontrolled pain 15.2%  
Adverse effects 28.8%  
Uncontrolled pain and 
adverse effects 50.8%
More than 1 opioid 
switch required in 
7 patients (6%)
Riley18 Prospective 
case-controlled 
study
48 87% Morphine responders compared 
to morphine non responders:  
Confusion and drowsiness (P = 5 × 10-12)  
Pain relief (P = 2.4 × 10-6)  
Nightmares (P = 5 × 10-5)  
Nausea (P = 7.3 × 10-3)
More than 1 opioid 
switch required in 
4 patients (8.5%)
wirz21 Prospective 
uncontrolled study
50 64% Uncontrolled pain 60%  
Sedation 4%  
itch 2%  
Gastrointestinal effects 
(nausea, constipation) 40%
Mercadante202 Prospective 
uncontrolled study
52 80% Uncontrolled pain 20%  
Adverse effects 16%  
Uncontrolled pain and adverse effects 64%
Kloke*15 Retrospective 
uncontrolled study
103 65% Uncontrolled pain 43%  
Adverse effects 20%  
Uncontrolled pain and adverse effects 15%
De Stoutz19 Retrospective 
uncontrolled study
80 73% Uncontrolled pain 16%  
Cognitive failure 39%  
Hallucinations 24%  
Myoclonus 11%  
Nausea 9%  
Local irritation 1%
More than 1 opioid 
switch required in 
some patients
aStudies included changing from one opioid to another in order to improve pain and side-effect profile (ie, opioid switching) and also for other reasons (opioid rotation).Journal of Pain Research 2009:2 141
Opioids for cancer pain Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of codeine to morphine, found in 3% of Caucasians.33 There 
is a case report of fatal neonatal opioid toxicity in a child 
who was being breastfed by a CYP2D6 ultra-rapid metabo-
lizing mother.34,35 Variation in at least 16 alleles has been 
shown to influence CYP2D6 activity.36 Recent data suggest 
that CYP2D6 phenotype also plays a role in response to 
tramadol.37 CYP2D6 gene duplication has been described 
as playing a role in development of respiratory depression 
on tramadol.38
The association between opioid response in cancer pain 
and a number of other SNPs in different genes has also been 
studied (see Table 3). In most of these studies morphine has 
been the predominant opioid used, with sparse data on the 
genetics of response to other opioids.39 To date the numbers 
of patients in these studies have been small and the number 
of SNPs studied has been limited.
Most genes are chosen for genetic association studies 
on the basis of the biological role which they play in the 
pharmacokinetic or pharmacodynamic pathways for the 
drug. The most frequently studied candidate gene involved in 
morphine analgesia is OPRM which codes for the mu-opioid 
receptor. Two hundred fifty-eight validated SNPs have 
been identified along the OPRM gene.40 The most com-
monly studied polymorphism in OPRM is rs1799971, also 
known as A118G. This SNP which occurs in exon 1and 
results in an amino acid change (asparagine to aspartate) 
in the extracellular N-terminus of the receptor. This in turn 
results in loss of a potential N terminus glycosylation site 
which theoretically may alter ligand binding and receptor 
dimerization.41,42 This SNP occurs with a frequency of 0% 
to 48.9%, depending on the population being studied.43 The 
actual functional consequences of this polymorphism are 
unclear. One study examined mRNA expression in human 
brain tissue and reported a reduction in mRNA and OPRM 
protein (receptor) levels associated with the variant.44 A fur-
ther study demonstrated altered receptor binding affinity.45 
Another study however reported no difference in binding 
affinities between wild type receptor and the mu-opioid 
receptor coded for by this variant.46
Clinical genetic association studies, although somewhat 
inconsistent, suggest that rs1799971 A118G does play a 
role in morphine response. The details of association with 
morphine response in cancer pain are found in Table 3. 
Generally these studies suggest that carriage of the G allele 
(variant) of this SNP is associated with a poor response to 
morphine for cancer pain. Patients with the G allele tend to 
require higher doses of and experience less pain relief from 
morphine.47–49
This polymorphism was also been associated with 
differential central effects from morphine and M6G in a 
single blind two-way crossover study of 12 healthy volunteers 
who were administered IV morphine and IV M6G. The con-
centration of drug required to achieve 50% pupil constriction 
was used as a measure of drug potency. Serum concentrations 
of morphine and M6G were measured at regular set intervals 
using liquid chromatography tandem mass spectrometry. 
Subjects with carrying the variant (ie, genotype AG or GG) 
required larger doses of M6G to achieve 50% pupil constric-
tion than subjects with AA (wild-type) genotype. There was 
no difference in the effects of morphine on pupil constriction 
between the genotypes.50
RNA variation: spice variants
A single stretch of DNA can result in a number of different 
protein products, mainly through RNA modification. Recent 
work into genetic variation at an RNA level has proposed the 
concept of multiple mu-opioid receptor subtypes through 
a process known as alternative splicing. Splicing refers 
to a process of post-transcription modification in which 
intronic material is removed and exons are joined together 
to form messenger RNA (mRNA). mRNA is subsequently 
translated into the protein product, which in the case of 
OPRM is the mu-opioid receptor. Different splicing products 
with potentially different functions can be formed through 
different arrangements of the exons in the mRNA.
The concept of multiple receptor subtypes is not new, 
suggested by a) incomplete cross tolerance between various 
mu-opioid receptor agonists51 and b) differential actions 
of mu-opioid receptor agonists and antagonists.52 Sophis-
ticated rodent studies using inbred strains and knockout 
strains have further strengthened this concept. Mu-opioid 
receptor knockout mice demonstrate a complete loss of 
all mu-opioid receptors from the brain, suggesting that is 
mu-opioid receptor subtypes exists, they must be derived 
from the same gene.53 The CXBK mouse is an inbred strain 
which is poorly responsive to opioids. When administered 
morphine, these mice experience reduced analgesia. CXBK 
mice have reduced levels of OPRM1 mRNA, with subse-
quent reduced expression of mu-opioid receptors and less 
signal transduction.54 CXBK mice, however, retain analgesic 
sensitivity to morphine-6-glucuronide (M-6-G), heroin and 
fentanyl, all mu-opioid receptor agonists, suggesting that 
M-6-G, heroin, and fentanyl act via a different mu-opioid 
receptor than morphine.55
The structure of the human mu-opioid receptor 
has been cloned.56 OPRM was initially thought to be made Journal of Pain Research 2009:2 142
Droney and Riley Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
3
 
S
u
m
m
a
r
y
 
t
a
b
l
e
 
o
f
 
p
h
a
r
m
a
c
o
g
e
n
e
t
i
c
s
 
a
n
d
 
r
e
s
p
o
n
s
e
 
t
o
 
m
o
r
p
h
i
n
e
 
i
n
 
h
u
m
a
n
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
c
a
n
c
e
r
 
p
a
i
n
a
S
N
P
/
s
C
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
S
t
r
o
n
g
e
s
t
 
P
 
v
a
l
u
e
M
e
t
h
o
d
 
o
f
 
p
h
e
n
o
t
y
p
e
 
d
e
fi
n
i
t
i
o
n
T
y
p
e
 
o
f
 
s
t
u
d
y
S
t
u
d
y
 
p
o
p
u
l
a
t
i
o
n
S
i
n
g
l
e
 
g
e
n
e
 
e
f
f
e
c
t
O
P
R
M
 
(
m
u
-
o
p
i
o
i
d
 
r
e
c
e
p
t
o
r
 
g
e
n
e
)
M
a
i
n
 
s
i
t
e
 
o
f
 
a
c
t
i
o
n
 
f
o
r
 
m
o
r
p
h
i
n
e
 
a
n
d
 
o
t
h
e
r
 
o
p
i
o
i
d
s
O
P
R
M
 
A
1
1
8
G
 
(
r
s
1
7
9
9
9
7
1
)
 
a
n
d
 
o
t
h
e
r
s
G
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
h
i
g
h
e
r
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
 
r
e
q
u
i
r
e
d
 
t
o
 
a
c
h
i
e
v
e
 
a
d
e
q
u
a
t
e
 
p
a
i
n
 
c
o
n
t
r
o
l
.
 
N
o
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
s
i
d
e
-
e
f
f
e
c
t
s
 
s
c
o
r
e
s
0
.
0
0
6
T
o
t
a
l
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
.
 
A
v
e
r
a
g
e
 
p
a
i
n
 
s
c
o
r
e
,
 
1
1
-
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
.
 
S
i
d
e
-
e
f
f
e
c
t
s
 
s
c
o
r
e
d
 
o
n
 
4
 
p
o
i
n
t
 
v
e
r
b
a
l
 
r
a
t
i
n
g
 
s
c
o
r
e
.
 
M
e
t
a
b
o
l
i
t
e
s
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
l
i
q
u
i
d
 
c
h
r
o
m
a
t
o
g
r
a
p
h
y
 
m
a
s
s
 
s
p
e
c
t
r
o
m
e
t
r
y
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
9
9
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
c
o
n
t
r
o
l
l
e
d
 
p
a
i
n
 
(
a
v
e
r
a
g
e
 
p
a
i
n
 

4
)
4
7
O
P
R
M
 
A
1
1
8
G
 
(
r
s
1
7
9
9
9
7
1
)
G
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
l
o
w
e
r
 
c
h
a
n
g
e
 
i
n
 
p
a
i
n
 
s
c
o
r
e
s
 
(
N
R
S
)
 
b
e
t
w
e
e
n
 
b
a
s
e
l
i
n
e
 
a
n
d
 
7
 
d
a
y
s
 
o
f
 
m
o
r
p
h
i
n
e
 
t
r
e
a
t
m
e
n
t
0
.
0
0
0
1
5
-
p
o
i
n
t
 
v
e
r
b
a
l
 
r
a
t
i
n
g
 
s
c
a
l
e
 
a
n
d
 
1
1
-
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
.
 
C
h
a
n
g
e
 
i
n
 
N
R
S
 
b
e
t
w
e
e
n
 
b
a
s
e
l
i
n
e
 
a
n
d
 
7
 
d
a
y
s
 
o
f
 
m
o
r
p
h
i
n
e
 
t
r
e
a
t
m
e
n
t
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
M
u
l
t
i
p
l
e
 
t
i
m
e
 
p
o
i
n
t
s
 
w
i
t
h
 
8
 
w
e
e
k
 
f
o
l
l
o
w
-
u
p
1
3
7
 
p
a
t
i
e
n
t
s
 
s
t
a
r
t
i
n
g
 
m
o
r
p
h
i
n
e
 
f
o
r
 
c
a
n
c
e
r
 
p
a
i
n
4
8
O
P
R
M
 
A
1
1
8
G
 
(
r
s
1
7
9
9
9
7
1
)
G
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
h
i
g
h
e
r
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
.
 
N
o
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
p
a
i
n
 
s
c
o
r
e
s
0
.
0
1
2
T
o
t
a
l
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
.
 
A
v
e
r
a
g
e
 
p
a
i
n
 
s
c
o
r
e
,
 
1
1
-
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
0
7
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
o
n
 
m
o
r
p
h
i
n
e
4
9
O
P
R
M
 
A
1
1
8
G
 
(
r
s
1
7
9
9
9
7
1
)
,
 
r
s
5
8
9
0
4
6
 
a
n
d
 
o
t
h
e
r
s
N
o
t
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
m
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
 
a
n
d
 
n
o
n
-
r
e
s
p
o
n
d
e
r
N
S
M
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
s
 
w
e
r
e
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
 
f
o
r
 
a
t
 
l
e
a
s
t
 
1
 
m
o
n
t
h
 
w
i
t
h
 
g
o
o
d
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
 
m
i
n
i
m
a
l
 
s
i
d
e
-
e
f
f
e
c
t
s
 
M
o
r
p
h
i
n
e
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
 
h
a
d
 
i
n
a
d
e
q
u
a
t
e
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
/
o
r
 
i
n
t
o
l
e
r
a
b
l
e
 
s
i
d
e
-
e
f
f
e
c
t
s
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
1
8
6
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
0
3
C
O
M
T
 
(
C
a
t
e
c
h
o
l
-
O
-
m
e
t
h
y
l
t
r
a
n
s
f
e
r
a
s
e
 
g
e
n
e
)
C
O
M
T
 
c
o
d
e
s
 
f
o
r
 
a
n
 
e
n
z
y
m
e
 
w
h
i
c
h
 
i
s
 
i
n
v
o
l
v
e
d
 
i
n
 
c
a
t
e
c
h
o
l
a
m
i
n
e
 
m
e
t
a
b
o
l
i
s
m
C
O
M
T
 
v
a
l
1
5
8
M
e
t
 
(
r
s
4
6
8
0
)
 
a
n
d
 
o
t
h
e
r
s

1
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
m
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
 
a
n
d
 
n
o
n
-
r
e
s
p
o
n
d
e
r
0
.
0
0
3
M
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
s
 
w
e
r
e
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
 
f
o
r
 
a
t
 
l
e
a
s
t
 
1
 
m
o
n
t
h
 
w
i
t
h
 
g
o
o
d
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
 
m
i
n
i
m
a
l
 
s
i
d
e
-
e
f
f
e
c
t
s
.
 
M
o
r
p
h
i
n
e
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
 
h
a
d
 
i
n
a
d
e
q
u
a
t
e
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
/
o
r
 
i
n
t
o
l
e
r
a
b
l
e
 
s
i
d
e
-
e
f
f
e
c
t
s
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
2
8
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
0
4
C
O
M
T
 
v
a
l
1
5
8
M
e
t
 
(
r
s
4
6
8
0
)
 
a
n
d
 
o
t
h
e
r
s

1
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
c
e
n
t
r
a
l
 
s
i
d
e
-
e
f
f
e
c
t
s
 
o
f
 
d
r
o
w
s
i
n
e
s
s
 
a
n
d
 
c
o
n
f
u
s
i
o
n
/
h
a
l
l
u
c
i
n
a
t
i
o
n
s
0
.
0
0
3
S
i
d
e
-
e
f
f
e
c
t
s
 
s
c
o
r
e
d
 
o
n
 
a
 
4
-
p
o
i
n
t
 
s
u
b
j
e
c
t
i
v
e
 
c
a
t
e
g
o
r
i
c
a
l
 
s
c
a
l
e
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
2
8
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
0
4Journal of Pain Research 2009:2 143
Opioids for cancer pain Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
C
O
M
T
 
v
a
l
1
5
8
M
e
t
 
(
r
s
4
6
8
0
)
v
a
l
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
h
i
g
h
e
r
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
 
r
e
q
u
i
r
e
m
e
n
t
s
.
 
N
o
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
s
e
r
u
m
 
m
o
r
p
h
i
n
e
 
a
n
d
 
m
e
t
a
b
o
l
i
t
e
s
 
a
n
d
 
s
i
d
e
-
e
f
f
e
c
t
 
s
c
o
r
e
s
0
.
0
2
5
T
o
t
a
l
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
.
 
 
A
v
e
r
a
g
e
 
p
a
i
n
 
s
c
o
r
e
,
 
1
1
-
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
.
 
S
i
d
e
-
e
f
f
e
c
t
s
 
s
c
o
r
e
d
 
o
n
 
4
-
p
o
i
n
t
 
v
e
r
b
a
l
 
r
a
t
i
n
g
 
s
c
o
r
e
.
 
M
e
t
a
b
o
l
i
t
e
s
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
l
i
q
u
i
d
 
c
h
r
o
m
a
t
o
g
-
r
a
p
h
y
 
m
a
s
s
 
s
p
e
c
t
r
o
m
e
t
r
y
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
0
7
 
p
a
t
i
e
n
t
s
 
o
n
 
m
o
r
p
h
i
n
e
 
f
o
r
 
c
a
n
c
e
r
 
p
a
i
n
2
0
5
r
s
4
8
1
8
,
 
C
O
M
T
 
v
a
l
1
5
8
M
e
t
 
(
r
s
4
6
8
0
)
,
 
r
s
6
2
6
9
,
 
r
s
7
4
0
6
0
3
 
a
n
d
 
o
t
h
e
r
s
 
(
h
a
p
l
o
t
y
p
e
 
c
o
n
s
t
r
u
c
t
i
o
n
)

1
 
h
a
p
l
o
t
y
p
e
s
 
a
n
d
 
a
l
l
e
l
e
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
 
r
e
q
u
i
r
e
m
e
n
t
s
.
 
N
o
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
s
e
r
u
m
 
m
o
r
p
h
i
n
e
 
a
n
d
 
m
e
t
a
b
o
l
i
t
e
s
 
a
n
d
 
s
i
d
e
-
e
f
f
e
c
t
 
s
c
o
r
e
s
0
.
0
0
6
 
(
h
a
p
l
o
t
y
p
e
 
a
n
a
l
y
s
i
s
)
T
o
t
a
l
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
.
 
A
v
e
r
a
g
e
 
p
a
i
n
 
s
c
o
r
e
,
 
1
1
-
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
.
 
S
i
d
e
-
e
f
f
e
c
t
s
 
s
c
o
r
e
d
 
o
n
 
4
-
p
o
i
n
t
 
v
e
r
b
a
l
 
r
a
t
i
n
g
 
s
c
o
r
e
.
 
M
e
t
a
b
o
l
i
t
e
s
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
l
i
q
u
i
d
 
c
h
r
o
m
a
t
o
g
r
a
p
h
y
 
m
a
s
s
 
s
p
e
c
t
r
o
m
e
t
r
y
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
0
7
 
p
a
t
i
e
n
t
s
 
o
n
 
m
o
r
p
h
i
n
e
 
f
o
r
 
c
a
n
c
e
r
 
p
a
i
n
2
0
6
C
O
M
T
 
v
a
l
1
5
8
M
e
t
 
(
r
s
4
6
8
0
)
v
a
l
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
h
i
g
h
e
r
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
 
r
e
q
u
i
r
e
m
e
n
t
s
.
 
N
o
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
p
a
i
n
 
s
c
o
r
e
s
0
.
0
2
T
o
t
a
l
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
.
 
A
v
e
r
a
g
e
 
p
a
i
n
 
s
c
o
r
e
,
 
1
1
-
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
0
7
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
o
n
 
m
o
r
p
h
i
n
e
4
9
M
D
R
 
(
M
u
l
t
i
-
D
r
u
g
 
R
e
s
i
s
t
a
n
c
e
 
g
e
n
e
)
T
h
i
s
 
g
e
n
e
 
c
o
d
e
s
 
f
o
r
 
p
-
g
l
y
c
o
p
r
o
t
e
i
n
 
w
h
i
c
h
 
i
s
 
i
n
v
o
l
v
e
d
 
i
n
 
d
r
u
g
 
t
r
a
n
s
f
e
r
 
a
c
r
o
s
s
 
t
h
e
 
b
l
o
o
d
 
b
r
a
i
n
 
b
a
r
r
i
e
r
r
s
1
1
2
8
5
0
3
,
 
r
s
2
0
3
2
5
8
2
,
 
M
D
R
 
C
3
4
3
5
T
 
(
r
s
1
0
4
5
6
4
2
)
 
a
n
d
 
o
t
h
e
r
s

1
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
c
e
n
t
r
a
l
 
s
i
d
e
-
e
f
f
e
c
t
s
 
o
f
 
d
r
o
w
s
i
n
e
s
s
 
a
n
d
 
c
o
n
f
u
s
i
o
n
/
h
a
l
l
u
c
i
n
a
t
i
o
n
s
0
.
0
0
0
3
S
i
d
e
-
e
f
f
e
c
t
s
 
s
c
o
r
e
d
 
o
n
 
a
 
4
 
p
o
i
n
t
 
s
u
b
j
e
c
t
i
v
e
 
c
a
t
e
g
o
r
i
c
a
l
 
s
c
a
l
e
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
2
8
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
0
4
M
D
R
1
 
C
3
4
3
5
T
 
(
r
s
1
0
4
5
6
4
2
)
C
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
l
o
w
e
r
 
c
h
a
n
g
e
 
i
n
 
p
a
i
n
 
s
c
o
r
e
s
 
(
N
R
S
)
 
b
e
t
w
e
e
n
 
b
a
s
e
l
i
n
e
 
a
n
d
 
7
 
d
a
y
s
 
o
f
 
m
o
r
p
h
i
n
e
 
t
r
e
a
t
m
e
n
t
0
.
0
0
1
5
-
p
o
i
n
t
 
v
e
r
b
a
l
 
r
a
t
i
n
g
 
s
c
a
l
e
 
a
n
d
 
1
1
 
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
.
 
C
h
a
n
g
e
 
i
n
 
N
R
S
 
b
e
t
w
e
e
n
 
b
a
s
e
l
i
n
e
 
a
n
d
 
7
 
d
a
y
s
 
o
f
 
m
o
r
p
h
i
n
e
 
t
r
e
a
t
m
e
n
t
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
M
u
l
t
i
p
l
e
 
t
i
m
e
 
p
o
i
n
t
s
 
w
i
t
h
 
8
 
w
e
e
k
 
f
o
l
l
o
w
-
u
p
1
3
7
 
p
a
t
i
e
n
t
s
 
s
t
a
r
t
i
n
g
 
m
o
r
p
h
i
n
e
 
f
o
r
 
c
a
n
c
e
r
 
p
a
i
n
4
8
A
R
R
B
2
 
(
B
-
a
r
r
e
s
t
i
n
-
2
)
T
h
i
s
 
g
e
n
e
 
c
o
d
e
s
 
f
o
r
 
a
 
p
r
o
t
e
i
n
 
w
h
i
c
h
 
i
s
 
i
n
v
o
l
v
e
d
 
i
n
 
i
n
t
r
a
c
e
l
l
u
l
a
r
 
r
e
c
e
p
t
o
r
 
t
r
a
f
fi
c
k
i
n
g
 
a
n
d
 
d
e
g
r
a
d
a
t
i
o
n
2
0
7
,
2
0
8
T
8
6
6
2
C
 
(
r
s
1
0
4
5
2
8
0
)
,
 
G
1
1
1
4
3
A
(
r
s
2
0
3
6
6
5
7
)
 
a
n
d
 
o
t
h
e
r
s

1
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
 
b
e
t
w
e
e
n
 
m
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
 
a
n
d
 
n
o
n
-
r
e
s
p
o
n
d
e
r
0
.
0
1
3
M
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
s
 
w
e
r
e
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
 
f
o
r
 
a
t
 
l
e
a
s
t
 
1
 
m
o
n
t
h
 
w
i
t
h
 
g
o
o
d
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
 
m
i
n
i
m
a
l
 
s
i
d
e
-
e
f
f
e
c
t
s
.
 
M
o
r
p
h
i
n
e
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
 
h
a
d
 
i
n
a
d
e
q
u
a
t
e
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
/
o
r
 
i
n
t
o
l
e
r
a
b
l
e
 
s
i
d
e
-
e
f
f
e
c
t
s
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
1
8
6
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
0
3
S
T
A
T
6
 
(
s
i
g
n
a
l
 
t
r
a
n
s
d
u
c
e
r
 
a
n
d
 
a
c
t
i
v
a
t
o
r
 
o
f
 
t
r
a
n
s
c
r
i
p
t
i
o
n
 
g
e
n
e
)
C
-
1
7
4
T
(
r
s
1
6
7
7
6
9
)
,
 
C
9
0
6
5
T
(
r
s
8
4
1
7
1
8
)
 
a
n
d
 
o
t
h
e
r
s
T
 
a
l
l
e
l
e
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
m
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
 
a
n
d
 
n
o
n
-
r
e
s
p
o
n
d
e
r
0
.
0
2
6
M
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
s
 
w
e
r
e
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
 
f
o
r
 
a
t
 
l
e
a
s
t
 
1
 
m
o
n
t
h
 
w
i
t
h
 
g
o
o
d
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
 
m
i
n
i
m
a
l
 
s
i
d
e
-
e
f
f
e
c
t
s
.
 
M
o
r
p
h
i
n
e
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
 
h
a
d
 
i
n
a
d
e
q
u
a
t
e
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
/
o
r
 
i
n
t
o
l
e
r
a
b
l
e
 
s
i
d
e
-
e
f
f
e
c
t
s
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
1
8
6
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
0
3
(
C
o
n
t
i
n
u
e
d
)Journal of Pain Research 2009:2 144
Droney and Riley Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
T
a
b
l
e
 
3
 
(
C
o
n
t
i
n
u
e
d
)
S
N
P
/
s
C
l
i
n
i
c
a
l
 
r
e
s
p
o
n
s
e
S
t
r
o
n
g
e
s
t
 
P
 
v
a
l
u
e
M
e
t
h
o
d
 
o
f
 
p
h
e
n
o
t
y
p
e
 
d
e
fi
n
i
t
i
o
n
T
y
p
e
 
o
f
 
s
t
u
d
y
S
t
u
d
y
 
p
o
p
u
l
a
t
i
o
n
S
i
n
g
l
e
 
g
e
n
e
 
e
f
f
e
c
t
U
G
T
2
B
7
 
(
U
D
P
 
g
l
y
c
o
s
y
l
t
r
a
n
s
f
e
r
a
s
e
 
2
 
g
e
n
e
)
.
 
 
T
h
i
s
 
e
n
z
y
m
e
 
i
s
 
i
n
v
o
l
v
e
d
 
i
n
 
t
h
e
 
h
e
p
a
t
i
c
 
m
e
t
a
b
o
l
i
s
m
 
o
f
 
m
o
r
p
h
i
n
e
A
2
0
9
8
T
(
r
s
7
4
3
8
2
8
4
)
,
 
C
2
0
9
9
T
(
r
s
7
4
3
9
3
6
6
)
N
o
t
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
b
e
t
w
e
e
n
 
m
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
 
a
n
d
 
n
o
n
-
r
e
s
p
o
n
d
e
r
N
S
M
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
s
 
w
e
r
e
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
 
f
o
r
 
a
t
 
l
e
a
s
t
 
1
 
m
o
n
t
h
 
w
i
t
h
 
g
o
o
d
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
 
m
i
n
i
m
a
l
 
s
i
d
e
-
e
f
f
e
c
t
s
.
 
M
o
r
p
h
i
n
e
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
 
h
a
d
 
i
n
a
d
e
q
u
a
t
e
 
p
a
i
n
 
c
o
n
t
r
o
l
 
a
n
d
/
o
r
 
i
n
t
o
l
e
r
a
b
l
e
 
s
i
d
e
-
e
f
f
e
c
t
s
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
1
8
6
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
0
3
U
G
T
2
B
7
 
H
2
6
8
Y
 
a
n
d
 
o
t
h
e
r
s
N
o
t
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
s
e
r
u
m
 
m
o
r
p
h
i
n
e
 
a
n
d
 
m
e
t
a
b
o
l
i
t
e
 
l
e
v
e
l
s
N
S
M
e
t
a
b
o
l
i
t
e
s
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
l
i
q
u
i
d
 
c
h
r
o
m
a
t
o
g
r
a
p
h
y
 
m
a
s
s
 
s
p
e
c
t
r
o
m
e
t
r
y
.
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
1
7
5
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
0
9
U
G
T
1
A
1
*
2
8
,
 
U
G
T
2
B
7
 
H
2
6
8
Y
N
o
t
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
s
e
r
u
m
 
m
o
r
p
h
i
n
e
 
a
n
d
 
m
e
t
a
b
o
l
i
t
e
 
l
e
v
e
l
s
N
S
M
e
t
a
b
o
l
i
t
e
s
 
m
e
a
s
u
r
e
d
 
u
s
i
n
g
 
l
i
q
u
i
d
 
c
h
r
o
m
a
t
o
g
r
a
p
h
y
 
m
a
s
s
 
s
p
e
c
t
r
o
m
e
t
r
y
.
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
7
0
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
m
o
r
p
h
i
n
e
2
1
0
C
o
m
b
i
n
e
d
 
e
f
f
e
c
t
 
o
f
 

1
 
g
e
n
e
O
P
R
M
/
C
O
M
T
C
O
M
T
 
v
a
l
1
5
8
M
e
t
 
(
r
s
4
6
8
0
)
 
O
P
R
M
 
A
1
1
8
G
 
(
r
s
1
7
9
9
9
7
1
)
O
P
R
M
 
A
A
/
C
O
M
T
 
M
e
t
/
M
e
t
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
l
o
w
e
s
t
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
 
r
e
q
u
i
r
e
m
e
n
t
s
0
.
0
1
2
T
o
t
a
l
 
d
a
i
l
y
 
m
o
r
p
h
i
n
e
 
d
o
s
e
.
 
A
v
e
r
a
g
e
 
p
a
i
n
 
s
c
o
r
e
,
 
1
1
-
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
0
7
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
o
n
 
m
o
r
p
h
i
n
e
4
9
C
O
M
T
/
M
D
R
C
O
M
T
 
v
a
l
1
5
8
M
e
t
 
(
r
s
4
6
8
0
)
,
 
M
D
R
 
C
3
4
3
5
T
 
(
r
s
1
0
4
5
6
4
2
)
 
a
n
d
 
o
t
h
e
r
s
C
o
m
b
i
n
a
t
i
o
n
 
o
f
 
C
O
M
T
/
M
D
R
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
r
e
d
u
c
e
d
 
c
e
n
t
r
a
l
 
s
i
d
e
-
e
f
f
e
c
t
s
 
o
f
 
d
r
o
w
s
i
n
e
s
s
 
a
n
d
 
c
o
n
f
u
s
i
o
n
/
h
a
l
l
u
c
i
n
a
t
i
o
n
s

0
.
0
0
0
1
S
i
d
e
-
e
f
f
e
c
t
s
 
s
c
o
r
e
d
 
o
n
 
a
 
4
-
p
o
i
n
t
 
s
u
b
j
e
c
t
i
v
e
 
c
a
t
e
g
o
r
i
c
a
l
 
s
c
a
l
e
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
S
i
n
g
l
e
 
t
i
m
e
 
p
o
i
n
t
2
2
8
 
c
a
n
c
e
r
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
o
r
a
l
 
m
o
r
p
h
i
n
e
.
 
M
o
r
p
h
i
n
e
 
r
e
s
p
o
n
d
e
r
s
 
a
n
d
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
2
0
4
O
P
R
M
/
M
D
R
1
O
P
R
M
 
A
1
1
8
G
 
(
r
s
1
7
9
9
9
7
1
)
 
M
D
R
1
 
C
3
4
3
5
T
 
(
r
s
1
0
4
5
6
4
2
)
O
P
R
M
 
A
A
/
M
D
R
1
 
T
T
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
g
r
e
a
t
e
s
t
 
c
h
a
n
g
e
 
i
n
 
p
a
i
n
 
s
c
o
r
e
s
 
(
N
R
S
)
 
b
e
t
w
e
e
n
 
b
a
s
e
l
i
n
e
 
a
n
d
 
7
 
d
a
y
s
 
o
f
 
m
o
r
p
h
i
n
e
 
t
r
e
a
t
m
e
n
t

0
.
0
0
0
0
1
5
-
p
o
i
n
t
 
v
e
r
b
a
l
 
r
a
t
i
n
g
 
s
c
a
l
e
 
a
n
d
 
1
1
-
p
o
i
n
t
 
N
R
S
 
(
0
–
1
0
)
.
P
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
.
 
M
u
l
t
i
p
l
e
 
t
i
m
e
 
p
o
i
n
t
s
 
w
i
t
h
 
8
 
w
e
e
k
 
f
o
l
l
o
w
-
u
p
1
3
7
 
p
a
t
i
e
n
t
s
 
s
t
a
r
t
i
n
g
 
m
o
r
p
h
i
n
e
 
f
o
r
 
c
a
n
c
e
r
 
p
a
i
n
4
8
a
S
t
u
d
i
e
s
 
i
n
v
o
l
v
i
n
g
 

1
 
g
e
n
e
/
c
l
i
n
i
c
a
l
 
o
u
t
c
o
m
e
 
a
r
e
 
p
r
e
s
e
n
t
e
d
 
s
e
p
a
r
a
t
e
l
y
 
h
e
r
e
.
 
O
n
l
y
 
s
t
u
d
i
e
s
 
e
x
a
m
i
n
i
n
g
 
r
e
s
p
o
n
s
e
 
t
o
 
o
p
i
o
i
d
s
 
f
o
r
 
c
a
n
c
e
r
 
p
a
i
n
 
a
r
e
 
i
n
c
l
u
d
e
d
 
h
e
r
e
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
N
R
S
 
n
u
m
e
r
i
c
 
r
a
t
i
n
g
 
s
c
a
l
e
;
 
N
S
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
.Journal of Pain Research 2009:2 145
Opioids for cancer pain Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
up of 4 exons (although more recent work suggests that it is 
in fact much more complex).57 Each exon is thought to be 
important for expression of different parts of the mu-opioid 
receptor. Exon 1 codes for the amino-terminal of the receptor 
and exons 1, 2 and 3 code for the transmembrane domains and 
intra/extracelluler loops.58 Exon 4 codes for the distal portion 
of the carboxyl chain of the receptor which is important in 
coupling the receptor to intracellular signalling systems and 
events. Knockout animals and antisense probes have been 
used to examine the impact of blocking expression of parts 
of a gene of interest. Rodents without expression of exon 
1 express significantly reduced morphine analgesia but retain 
sensitivity to M-6-G.59,60 Conversely, rodents with loss of 
exon 2 expression exhibit decreased M-6-G and not morphine 
analgesia.59 These data suggest that morphine and M-6-G 
may act on different mu-opioid receptor subtypes, which may 
be brought about through variation at an RNA level. Even 
more intriguing is that although antisense blockade of exon 
1 expression inhibited supraspinal morphine analgesia, it did 
not have any effect on spinal morphine analgesia, suggest-
ing that perhaps different mu-opioid receptors are involved 
in both processes.61 Antisense blockade of exon 4 inhibited 
all morphine effects.59,61 Immunohistochemical labelling of 
mu-opioid receptor splice variants demonstrated differential 
distribution in the brain and spinal cord suggesting region 
specific processing of OPRM into different mu-opioid recep-
tor subtypes.62
Practical challenges of examining human brain RNA 
means that most research in this area has been carried out in 
vitro using cell lines expressing mu-opioid receptors.63 10 
human splice variants have been identified resulting from 
alternative splicing at exon 4.63,64 Since exons 1 to 3 remain 
conserved, all of these splice variants bind mu-opioid 
agonists, but there are differences in terms of function, eg, 
receptor internalization and regional distribution.61 One study 
examining human brain tissue resected at time of temporal 
lobectomy for epilepsy demonstrated the presence of mu-
opioid receptor splice variants though real time reverse 
transcriptase polymerase chain reaction.65
Alternative splicing of delta- and kappa-opioid receptors 
has also been demonstrated.66
Some human data support the role of splice variants in 
pain perception. A recent study by Diatchenko et al analyzed 
patterns of genetic material between mice and humans. 
Although there are differences in the structure of mouse and 
human OPRM, this study demonstrated that a) most mouse 
OPRM exons (of which there are 20) also exist in humans 
and b) the architecture of the human OPRM is probably more 
complex than previously thought. A SNP, rs563649, was 
identified which was associated with altered pain response 
and which was also associated with differential translation 
of splice variants of mu-opioid receptor. This SNP was not 
however statistically associated with morphine analgesic 
response to experimental ischemic pain. This study does 
suggest an association between genetic variation at a DNA 
level (SNPs) and variation at an RNA level.57
To date no studies have been carried out examining 
the association between opioid receptor expression/splice 
variants and response to morphine in cancer patients in the 
clinical setting.
Protein variation: receptor dimerization
Finally, even after the genetic code is translated into a protein 
product, modifications and variation in function may occur 
through the process of receptor dimerization.
Morphine acts primarily through the mu-opioid recep-
tor. Animal studies have demonstrated that disruption of 
the mu-opioid receptor gene abolishes the analgesic effect 
of morphine despite the presence of functional delta- and 
kappa-opioid receptors.67 However binding studies suggest 
that morphine does bind to delta and kappa receptors, albeit 
with less affinity than to mu-opioid receptors.68,69 Although 
the role of delta- and kappa-opioid receptors in morphine 
response is not entirely clear, there is a suggestion that opioid 
receptors interact with each other and influence function.70–73 
For example delta-receptor knockout mice do not develop 
analgesic tolerance to morphine.74 Opioid receptors can form 
homo and hetero-dimers, thus producing novel functional 
properties through altered ligand binding and differential 
intracellular receptor trafficking.75–77 Opioid receptor dimer-
ization adds further to the complexity of inter-individual 
variation in opioid response. There have been no clinical 
studies examining the role of opioid receptor dimers on 
analgesic response to morphine for cancer pain.
Recent advances in the use 
of opioids for cancer pain: alternative 
routes of opioid administration 
for breakthrough pain
Breakthrough pain is defined as “a transient exacerbation of 
pain that occurs either spontaneously or in relation to a specific 
predictable or unpredictable trigger, despite relatively stable 
and adequately controlled background pain”.78 There is some 
controversy surrounding the definition of this phenomenon but 
the reported prevalence is as high as 51% to 89%.79–81Journal of Pain Research 2009:2 146
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A number of issues arise when oral opioids are used to 
treat episodic breakthrough pain:
•    Increasing the regular dose of opioids in a patient with 
stable background pain may result in intolerable side-
effects.
•    Breakthrough pain often peaks to maximum intensity 
within minutes.82 The time to peak plasma concentration 
of oral morphine is 15 to 60 minutes.83 Therefore the effect 
of even immediate release (short-acting) oral opioids may 
last longer than the episode of breakthrough pain, mak-
ing these drugs less suitable for pains which have a short 
duration/onset of action.84
In recent years there has been considerable interest in the 
development of alternative routes of opioid administration 
for the management of breakthrough pain, with particular 
emphasis on the oral transmucosal/buccal and also intranasal 
routes.
The oral mucosa has a rich blood supply and this route of 
drug administration avoids hepatic first-pass metabolism.85 
Thus the onset of action of drugs administered transmucosally 
is potentially very rapid.86 Absorption is affected by lipophi-
licity of the drug, the fraction of drug which is ionized, the 
length of time with which the drug is in contact with the oral 
mucosa and also the pH.85 Lipophilic drugs such as fentanyl 
and buprenorphine are more rapidly absorbed than more 
hydrophilic drugs such as morphine.87
There have been a number of studies examining the use 
of oral transmucosal fentanyl citrate (OTFC) for the man-
agement of breakthough cancer pain. OFTC is available as a 
lozenge on a stick which is rubbed on the inside of the cheek 
over an approximately 15 minute period.88 Approximately 
25% of OFTC is absorbed via the buccal mucosa with the 
remaining 75% being swallowed. Overall the bioavail-
ability of OFTC is approximately 50%.89 The medium time 
to maximum plasma concentration is approximately 20 to 
40 minutes.88,90 Tmax is similar regardless of dose.91 A study 
of 92 cancer patients demonstrated larger reductions in pain 
intensity and better pain relief with OTFC compared to 
placebo.92 A randomized double-blind dose titration study 
involving 65 cancer patients with breakthrough pain dem-
onstrated a faster onset of analgesia with OFTC compared 
to the patient’s usual rescue analgesia (P  0.0001). In this 
study up to two episodes of breakthrough pain per day were 
treated with OTFC and all other episodes were treated with 
the patient’s usual rescue opioid.93 Another double-blind 
double-dummy randomized cross-over study was carried out 
comparing OTFC and morphine sulphate immediate release 
(MSIR). Pain intensity and pain relief scores were noted at 
15, 30, 45 and 60 minutes post dose. OTFC was associated 
with lower pain intensity and higher pain relief scores at all 
time points. A greater than 33% change in pain intensity at 
15 minutes was seen in 42.3% of episodes of pain treated with 
OFTC compared to 31.8% of episodes treated with MSIR 
(P  0.0001). In this study however only 69% (93/134) of 
patients were titrated to an effective OFTC dose, with 31% 
(41/134) withdrawing during the OFTC titration phase. Only 
75/93 patients used both OFTC and MSIR and thus were 
included in the efficacy analysis.94
Interestingly there appears to be no relationship between 
the effective dose of OFTC and the stable background opioid 
dose.93–95 Dose titration to an effective dose has been shown 
to be successful in 67 to 74% of patients.93,94,96 The useful-
ness of OFTC is limited if the patient has xerostomia97 or 
if the patient cannot manage the technique of applying it to 
the buccal mucosa.
More recently a novel effervescent transmucosal fentanyl 
buccal tablet (FBT) has been launched. This medication is 
designed to dissolve in 10 minutes when placed between 
the upper gum and cheek above a molar tooth.98 In a healthy 
volunteer open label cross-over study (N = 26) comparing 
OFTC and transmucosal FBT, the latter was found to have a 
higher absolute bioavailability (0.47 and 0.65 respectively). 
The time to maximum plasma concentration was shorter for 
transmucosal FBT compared to OFTC (47 and 91 minutes 
respectively).98 Of note the Tmax for OFTC in this study was 
actually considerably longer than reported in previous data, 
as discussed above.88,90 Transmucosal FBT appears better 
than placebo for the management of breakthrough pain in 
cancer patients99 It appears to be well tolerated in patients 
with mucositis, although the numbers involved in this study 
were small and the patients only experienced mild oral 
symptoms.100
Sublingual and intranasal fentanyl preparations have also 
been studied for breakthrough cancer pain.101–103 Sublingual 
and intranasal sufentanil is also used although this drug is 
not available in some countries. The data on sufentanil in 
cancer-related breakthrough pain consists of case series and 
small studies.104,105
Recent advances in the use 
of opioids for cancer pain: opioid 
antagonists for opioid-induced 
constipation
Constipation is one of the most common and troublesome 
side-effects of opioid medication. The published prevalence Journal of Pain Research 2009:2 147
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of constipation amongst patients taking opioids ranges from 
50% to 100%.106,107 Although the pathogenesis of constipa-
tion in cancer patients is multi-factorial,108 opioid medication 
plays a key role.106 There appears to be no dose-response 
relationship between opioids and constipation and unlike 
other side-effects such as drowsiness it is thought that for 
many patients tolerance to constipation is less likely to 
occur.109,110
Unlike opioid-analgesia, opioid-induced constipation is 
thought to be mediated predominately by peripheral rather 
than central mechanisms:111
•    In vitro experiments have demonstrated inhibitory effect 
of opioids on isolated gut muscle preparations.112
•    The constipating effects of centrally administered mor-
phine are abolished in animals in which the intestine has 
been rendered refractory to central influences through 
vagal resection. In the same animals however, subcutane-
ous morphine still produced anti-diarrheal action.113
•    Peripherally restricted opioid agonists such as loperamide 
which do not cross the blood-brain barrier also cause a 
reduction in gut transit.114
Mu-, delta-, and kappa-opioid receptors are found through-
out the gastrointestinal (GI) tract. Mu- and delta-opioid recep-
tors are found in both the myenteric and submucosal neurones 
while kappa-opioid receptors are predominately localized to 
the myenteric plexus.115 Morphine is thought to act directly 
on these peripheral opioid receptors in the bowel. Morphine 
administered either intravenously or intra-peritoneally accu-
mulates in the GI lumen.116 Mu-opioid receptor knockout mice 
studies demonstrate a key role of mu-opioid receptors in the 
role of opioid-induced constipation.117
Opioid receptor activation by opioid agonists causes 
a reduction in synaptic neurotransmitter release through 
activation of potassium channels,118 inhibition of calcium 
channels119 and a reduction in cAMP production.120 The 
overall effect is a reduction in acetylcholine release.106 
Opioids increase gut transit time and reduce the amount of 
fluid in the gut lumen. Forward propulsive contractions are 
inhibited, the stool spends a longer time in the gut lumen thus 
more fluid is reabsorbed and the stool becomes hard and dry. 
Opioids also have an indirect inhibitory effect on luminal 
fluid secretion via a complex mechanism involving 5-HT2 
receptors, α2-adrenoceptors and noradrenaline release.121
The management of constipation has traditionally been 
based around oral and rectal laxative use. A number of 
different agents are available but to date there is no evidence 
to suggest that any one laxative is superior to another, mainly 
because there have been few studies in this area.122 In recent 
years there has been a growing interest in the use of opioid 
receptor antagonists for the management of opioid-induced 
constipation. Theoretically opioid receptor blockade by an 
agent which does not cross the blood brain barrier would 
inhibit peripherally mediated GI side-effects without inter-
ruption of centrally mediated opioid analgesia. Three opioid 
receptor antagonists have been studied for this purpose: 
naloxone, methylnaltrexone, and alvimopan.
Naloxone
Naloxone is a pan-opioid receptor antagonist with a high 
affinity for mu-opioid receptors. Systemically administered 
naloxone is used to reverse life-threatening opioid toxicity 
and acts both peripherally and centrally. Oral naloxone how-
ever undergoes significant hepatic first pass glucuronidation 
to produce inactive metabolites,123 resulting in a very low 
(2%) oral bioavailability.124 The role of oral naloxone as 
a peripheral opioid antagonist in cancer patients has been 
examined in a number of small early studies with good 
effect.125–127 These studies however all demonstrated that the 
risk of precipitating pain or opioid withdrawal is substantial. 
The study by Sykes (N = 17) investigated the relationship 
between the dose of morphine and naloxone recommended 
a daily naloxone dose of 20% of the daily morphine dose, to 
a maximum of 5 mg.127 Another study in 22 cancer patients 
examined the relationship between morphine and effective 
naloxone dose when naloxone was titrated up to a maximum 
of 36 mg/day over a 4-day period to laxative use and opioid 
withdrawal (measured using a modified Himmelsbach with-
drawal scale). 23% (4/17) patients who completed the study 
experienced withdrawal symptoms. There was no relation-
ship demonstrated between morphine and effective naloxone 
dose.128 A further study in 9 patients demonstrated again that 
reversal of analgesia can still occur even when using lower 
doses of oral naloxone (6 to 12 mg/day).129
Recently there has been increased interest in the use 
of fixed dose combination of prolonged release (PR) oral 
oxycodone/naloxone as a method to provide analgesia 
while preventing opioid-induced constipation. A multicentre 
prospective placebo-controlled randomized double-blind par-
allel group phase II trial of 202 patients with severe chronic 
pain concluded that a 2:1 oxycodone:naloxone ratio was 
optimal in terms of safety and efficacy. Only 2.5% of study 
participants in this study had a cancer diagnosis.130 There 
was no significant difference in the mean pain intensities 
between treatment groups but there was an improvement 
in bowel function according to naloxone dose (p  0.05). 
Opioid withdrawal was not formally assessed in this study. Journal of Pain Research 2009:2 148
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Similar studies with 12 week follow-up periods comparing 
oxycodone/naloxone (2:1 ratio) PR with oxycodone PR 
alone demonstrated a significant improvement in bowel func-
tion in those taking the oxycodone/naloxone combination 
(P  0.0001).131,132 The maximum oxycodone dose (as part 
of the oxycodone/naloxone combination) in these studies was 
80 mg/day. Studies involving higher opioid doses with longer 
follow-up are warranted. This efficacy of this combination of 
oxycodone/naloxone combination in a predominately cancer 
population has not yet been reported.
Methylnaltrexone
Methylnaltrexone is a quaternary opioid antagonist which 
does not readily cross the blood brain barrier because of 
its reduced lipid solubility and increased polarity.133 It is a 
non-selective opioid antagonists with preferential mu-opioid 
receptor binding.134
Methylnaltrexone was originally studied in healthy 
volunteers  who  were  given  intravenous  placebo, 
placebo + morphine or methylnaltrexone + morphine. 
Methylnaltrexone significantly prevented morphine-induced 
decrease in oral-cecal transit but did not affect morphine 
analgesia.135 A randomized placebo-controlled trial was carried 
out involving 22 subjects who were enrolled on a methadone 
maintainance programme. All subjects who received 
methylnaltrexone (intravenous) had a laxation response with-
out opioid withdrawal or significant side-effects.136
A large randomized placebo-controlled phase III study 
using subcutaneous methylnaltrexone in patients with 
advanced illness has been published recently.137 Study 
subjects were administered 0.15 mg/kg methylnaltrexone 
SC (subcatenous) or placebo every second day for 2 weeks. 
The primary endpoints of this study were the proportion of 
subjects who had a rescue-free laxation (without the use of 
an enema or suppository) within 4 hours of the first dose 
and the proportion that had a rescue-free laxation within 
4 hours after 2 or more of the first 4 doses. Subjects were 
also assessed for overall pain scores and opioid withdrawal. 
Forty-eight percent of patients receiving methylnaltrexone 
had a rescue-free laxation within the first 4 hours after the first 
dose, compared to 15% who received placebo (P  0.001). 
Over the course of the first 4 doses, the proportion of patients 
having a rescue-free laxation within 4 hours ranged from 
38% to 48% in patients administered methylnaltrexone and 
7% to 15% in those given placebo. Approximately 50% of 
patients who had a rescue-free laxation within 4 hours had 
a response within 30 minutes, suggesting a rapid onset of 
action. There were no differences in pain scores between 
the methylnaltrexone and placebo groups and there was 
no evidence of significant opioid withdrawal. Only 59% 
(78/133) of study patients had a cancer diagnosis.137 A simi-
lar study in 154 patients with advanced illness receiving a 
single dose of 0.15 or 0.3 mg/kg SC methylnaltrexone or 
placebo demonstrated a laxation within 4 hours for 58% to 
62% of patients, depending on the dose administered.138 The 
authors of both these studies suggest that the reason why 
there appears to be a substantial proportion of patients who 
did not have a response to methylnaltrexone is perhaps due 
to non-opioid causes of constipation or constipation being 
mediated by central mechanisms.137,138 SC methylnaltrexone 
is licensed in the UK for palliative care patients as either 8 or 
12 mg depending on body weight.139
Oral methylnaltrexone has not been studied in cancer 
patients to date however there are data to suggest that it may 
be efficacious. In a small (N = 14) randomized controlled 
double-blind study of healthy volunteers methylnaltrexone 
prevented morphine-induced inhibitory effects on gut transit. 
There was no correlation between plasma concentrations of 
methylnaltrexone and the gut transit time and less than 1% of 
methylnaltrexone was excreted unchanged in the urine after 
6 hours. Therefore the authors concluded that oral methylnal-
trexone has a direct local bowel action.140 A further random-
ized controlled trial using an enteric-coated oral formulation 
demonstrated similarly efficacious results.141
Alvimopan
Alvimopan is a large oral peripherally restricted opioid 
antagonist with high affinity for mu-opioid receptors.142 It is 
metabolized in the gut.143 Systemic absorption ranges from 
0.03% in dogs to 6% in humans.144 Alvimopan reversed 
morphine-induced GI transit changes (as measured with the 
hydrogen breath test) in a double-blind, placebo-controlled, 
randomized, cross-over study in 14 volunteers. As part of 
the same study 45 patients undergoing tooth extraction were 
administered IV (intravenous) morphine and either oral 
alvimopan or placebo. Alvimopan did not alter analgesia and 
did not affect pupil constriction, confirming a lack of central 
activity.145 Oral alvimopan has also been studied with positive 
effect in post-operative ileus which is thought to be caused 
by activation of endogenous opioid receptors after bowel 
handling and also by exogenous opioids administered for pain 
control.146–148 Alvimopan was studied in a large trial (N = 522) 
of patients taking opioids for chronic non-cancer pain. It was 
associated with an increase in the number of spontaneous 
bowel movements compared to placebo (p  0.001). Adverse 
effects reported in this study included abdominal pain, nausea Journal of Pain Research 2009:2 149
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and diarrhea.149 In another large study involving 148 patients 
on opioids for non-malignant pain and 20 patients on opioid 
maintenance therapy for opioid abuse, a statistically larger 
proportion of patients receiving alvimopan than placebo 
achieved the primary endpoint of having a bowel motion 
within 8 hours.150 A large study in patients with cancer pain 
has been carried out but the final results have not yet been 
published fully. Concern about cardiovascular side-effects 
have been raised.151–153
Endogenous opioids are thought to play a role in the 
physiological regulation of gut function.154–156 Studies with 
opioid receptor antagonists support this idea. Early studies 
on isolated pieces of human ileum demonstrated increased 
muscle contraction when bathed in methylnaltrexone, even 
in the absence of morphine.157 Furthermore, in the absence 
of morphine, repeated intravenous administration in healthy 
human volunteers demonstrated a significant reduction in gut 
transit time (as measured by the hydrogen breath test).158 Oral 
naloxone has been shown to improve gut function in patients 
with chronic idiopathic constipation, although the numbers 
of patients studied was small.159 In vitro studies using guinea 
pig ileum demonstrated that alvimopan increases contractions 
and mechanical activity in morphine-naïve animals.160
The development of opioid receptor antagonists is excit-
ing, however a recent Cochrane review urges some caution.153 
These agents have not been directly compared against each 
other and they have not been compared to best current clinical 
practice with oral and rectal laxatives. In some of the larger 
studies, as constipation was a pre-requisite to entering the 
study, these individuals were clearly on an inadequate laxa-
tive regimen from the outset.137,149 Most data suggest that 
these agents are more efficacious than placebo in improving 
opioid-induced bowel dysfunction. Long-term safety data, 
however, is warranted. Animal studies suggest that chronic 
use of opioid-receptor antagonists may actually result in an 
increase in the number of receptors which in turn may lead 
to increased sensitivity to the constipating effect of opioid 
agonists and a resultant dependence on opioid antagonists.161 
It has also been suggested that the effects of opioid antago-
nists may in fact be proportional to the degree of opioid 
agonist tolerance and that patients on higher doses of opioid 
agonists may in fact be more at risk of adverse effects from 
drugs such as naloxone.162
Opioids for cancer pain: recent 
advances and future directions
Opioids are the mainstay of treatment for moderate to severe 
cancer pain. Unfortunately cancer pain is often managed 
inadequately. In a recent survey of 5084 cancer patients across 
Europe and Israel, 56% experienced moderate to severe 
pain at least monthly.163 In another European study of 3030 
palliative care patients, 32% had moderate or severe pain.11 
Although the variety and availability of different opioids 
has increased, the greatest advance in the use of opioids for 
cancer pain is undoubtedly an improved understanding of 
their mechanism of action. Physicians and researchers have 
become increasingly aware of marked inter-individual varia-
tion in response to opioids for cancer pain in terms of pain 
and side-effects. Exciting research in the field of pharmacoge-
nomics promises a greater understanding of the mechanisms 
underlying this variation. Novel modes of administration 
and the use of peripherally restricted opioid antagonists 
allow greater pain control while minimizing troublesome 
side-effects. There have been major advances in the use 
of functional neuroimaging (such as functional magnetic 
resonance imaging, fMRI) to identify and measure areas of 
the brain which are involved in pain perception164 and also 
response to opioids.165 This technology may be of use in the 
future in furthering our understanding of pain mechanisms 
and inter-individual variation in opioid response. The future 
of opioids for cancer pain lies in personalized prescribing 
ie, the tailored prescription of the correct dose of the correct 
drug for the individual patient.
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